August 14th 2024
Nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder, according to new research published in Addiction. In a literature review of studies definin
Clinical guidance news
August 13th 2024
Star Pharmaceuticals Limited has informed the MHRA of an error in the Patient Information Leaflet (PIL) for two batches of Diflucan Oral Suspension 40mg/ml. Section 6 of the PIL states “50mg of fluconazole per 5ml” instead of &ldqu
MHRA alert
August 12th 2024
DHSC has announced changes to the reimbursement of rivaroxaban from September: Moving to Category A: Rivaroxaban 2.5mg tablets Rivaroxaban 10mg tablets Moving to Category M: Rivaroxaban 15mg tablets Rivaroxaban 20mg tablets These addit
DM Zone news England Wales
August 9th 2024
Accord-UK Ltd is recalling multiple batches of Trandolapril 0.5, 2 and 4mg capsules as a precautionary measure after testing showed variability of the Trandolapril content beyond permitted levels. Healthcare professionals are asked to quarantine all
MHRA alert
August 8th 2024
The Department of Health and Social Care has redetermined the reimbursement prices for the following products, in the months as set out in the table, to reflect an increase in the NHS list price: Product Pack size Old NHS list pric
DM Zone news England Wales
August 8th 2024
MHRA has issued a class 4 alert for several batches of omeprazole GR capsules, omeprazole 40mg powder for solution for infusion vials, and Mezzopram dispersible gastro-resistant tablets. There is missing safety information in the Patient Information
MHRA alert
